India to Ireland: Sirolimus Export Trade Route

The India to Ireland Sirolimus corridor is one of India's established pharmaceutical export routes, with 6 shipments documented worth a combined $54.7K USD. The route is dominated by CONCORD BIOTECH LIMITED, which alone accounts for roughly 99% of all export value, reflecting the consolidated nature of India's sirolimus manufacturing sector.

Across 3 active suppliers, the average shipment value stands at $9.1K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 81% of all shipments, consistent with sirolimus's non-urgent bulk-order profile.

Shipment activity peaks during January–March, with an average transit time of 21 days port-to-port. The route has recorded an annual growth rate of 12.4%, placing it at rank #10 among India's top sirolimus export destinations globally.

On the import side, key buyers of Indian sirolimus in Ireland include DEREK GRUBB, HELEN MURRAY , HELEN MURRAY. DEREK GRUBB is the single largest importer with 3 shipments valued at $54.2K USD.

India's sirolimus exports to Ireland are driven primarily by a handful of large-scale manufacturers. CONCORD BIOTECH LIMITED with 3 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 3 active exporters signals a competitive but concentrated market — buyers in Ireland benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — CONCORD BIOTECH LIMITED, MAGICINE PHARMA , MAGICINE PHARMA — together account for 100% of total trade value on this route. The average shipment value of $9.1K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

Beyond the primary product category, shipments on this route include closely related formulations such as sirolimus rapamycin delayed release tablets 1.2mg b.no: rc23001b-r manufacturing .dt:02-aug-23 retest dt. jul 2025 and sirolimus rapamycin delayed release tablets 0.4mg b.no: rb23001b-r manufacturing .dt:02-aug-23 retest dt. jan 2025, suggesting that buyers in Ireland tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, DEREK GRUBB is the largest importer with 3 shipments worth $54.2K USD — representing 99% of all sirolimus imports from India on this route.